Psychiatric Quarterly

, Volume 63, Issue 1, pp 51–70 | Cite as

Clinical profile of clozapine: Adverse reactions and agranulocytosis

  • Jeffrey A. Lieberman
  • Allan Z. Safferman


The arrival of clozapine has been one of the most significant developments in antipsychotic drug treatment since the advent of chlorpromazine ushered in the psychopharmacologic era. However, its utilization has been significantly limited and complicated by its potential to cause adverse effects and agranulocytosis in particular. It must be emphasized that clozapine has a side effect profile that is in many ways distinct from standard typical antipsychotic drugs. Side effects with clozapine are common and range from the benign to the potentially lethal. The most common side effects include sedation, dizziness, and sialorrhea during sleep; the most serious are agranulocytosis, seizures and respiratory depression. Although side effects from clozapine are not necessarily preventable, they are for the most part manageable. Even with the most serious adverse effects, proper knowledge of the medication's actions, clinical vigilance, and prompt intervention can prevent the occurrence of significant morbidity and mortality as a consequence of clozapine treatment.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Delay J, Deniker P, Hart J: Traitment des etats d'excitation et d'agitation par une methode medicamenteuse derivée de l'hibernotherapie. Annales Medico-Psychologiques 110:267–273, 1952.Google Scholar
  2. 2.
    Meltzer HY. Clozapine: Mechanism of action in relation to its clinical advantages. In: Kales A.; Stefanis, C.N.; Talbott, J.A., eds. Recent Advances in Schizophrenia. New York: Springer-Verlag 237–246, 1990.Google Scholar
  3. 3.
    Kane, JM, Honigfeld G, Singer J, et al: Clozapine for the treatment resistant schizophrenic. Archives of General Psychiatry 45:789–796, 1988.Google Scholar
  4. 4.
    Meltzer HY, Bastani B, Kwon KY, et al: A prospective study of clozapine in treatment resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99:S68–72, 1989.Google Scholar
  5. 5.
    Lindstrom LH: A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology 99:S84–86, 1989.Google Scholar
  6. 6.
    Lieberman JA, Kane J, Johns C: Clozapine: Guidelines for clinical management. Journal of Clinical Psychiatry 50:329–338, 1989.Google Scholar
  7. 7.
    Safferman AZ, Lieberman JA, Kane J, et al: Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 17:247–261, 1991.Google Scholar
  8. 8.
    Fitton A, Heel RC: Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722–747, 1990.Google Scholar
  9. 9.
    Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: An atypical antipsychotic agent. Clinical Pharmacy 8:691–709, 1989.Google Scholar
  10. 10.
    Baldessarini RJ, Frankenburg FR: Clozapine. New England Journal of Medicine 324:746–754, 1991.Google Scholar
  11. 11.
    Farde L, Wiesel FA, Nordstrom AL, et al: D-1 and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28–31, 1989.Google Scholar
  12. 12.
    Coward DM, Imperato A, Urwyler S, et al: Biochemical and behavioural properties of clozapine. Psychopharmacology 99:S6-S12, 1989.Google Scholar
  13. 13.
    Richelson E: Pharmacology of neuroleptics in use in the United States. Journal of Clinical Psychiatry 46:8–14, 1985.Google Scholar
  14. 14.
    Andersen PH, Breastrup C: Evidence for different states of the dopamine D! receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. Journal of Neurochemistry 47:1822–1831, 1986.Google Scholar
  15. 15.
    Van-Tol HH, Bunzow JR, Guan HC, et al: Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610–614, 1991.Google Scholar
  16. 16.
    Lee T, Tank SW: Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Research 12:277–285, 1985.Google Scholar
  17. 17.
    Bolden C, Cusack B, Richelson E: Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. European Journal of Pharmacology 192:205–206, 1991.Google Scholar
  18. 18.
    Nash JF, Meltzer HY, Gudelsky GA: Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. European Journal of Pharmacology 151:463–469, 1988.Google Scholar
  19. 19.
    Drew KL, O'Connor WT, Kehr J, et al: Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. European Journal of Pharmacology 107:385–397, 1990.Google Scholar
  20. 20.
    Watling KJ, Beer MS, Stanton JA, et al: Interaction of the atypical neuroleptic clozapine with 5HT-3 receptors in the cerebral cortex and superior cervical ganglion of the rat. European Journal of Pharmacology 182:465–472, 1990.Google Scholar
  21. 21.
    Schmidt WJ, Krahling H, Ruhland M: Antagonism of AP-5-induced sniffing stereotype links Umespirone to atypical antipsychotics. Life Sciences 48:499–505, 1991.Google Scholar
  22. 22.
    Anderman B, Griffith RW: Clozapine-induced agranulocytosis: A situation report up to August 1976. European Journal of Clinical Pharmacology 11:193–198, 1977.Google Scholar
  23. 23.
    Amsler HA, Teerenhovi L, Barth E, et al: Agranulocytosis in patients treated with clozapine: A study of the Finnish epidemic. Acta Psychiatrica Scandinavica 11(3):193–198, 1977.Google Scholar
  24. 24.
    Krupp P, Barnes P: Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology S99:118–121, 1989.Google Scholar
  25. 25.
    Pisciotta AV: A brief review of drug-induced agranulocytosis. Journal of Clinical Psychiatry Monograph 8:22–29, 1990.Google Scholar
  26. 26.
    Vincent PC: Drug-induced aplastic anemia and agranulocytosis: Incidence and mechanisms. Drugs 31:52–63, 1986.Google Scholar
  27. 27.
    Krupp P. Sandoz, Ltd. Drug Monitoring Center, Basle, Switzerland.Google Scholar
  28. 28.
    Lieberman JA: Clozapine and agranulocytosis in the United States. Presented at the NIMH New Clinical Drug Evaluation Unit Program 31st Annual Meeting, Key Biscayne, Florida, May 28–31, 1991.Google Scholar
  29. 29.
    Alvir J, Lieberman JA, Schwimmer J: Clozapine and agranulocytosis: The U.S. postmarketing experience. Presented at the 7th International Conference on Pharmaco-epidemiology, Basle, Switzerland, August 26–29, 1991.Google Scholar
  30. 30.
    Gerson SL, Lieberman JA, Friedenberg WR, et al: Polypharmacy and fatal clozapine-associated agranulocytosis. Lancet 338:262, 1991.Google Scholar
  31. 31.
    Mandel A, Gross M: Agranulocytosis and phenothiazines. Diseases of the Nervous System 29:32–36, 1968.Google Scholar
  32. 32.
    Pisciotta AV: Agranulocytosis induced by certain phenothiazine derivatives. Journal of the American Medical Association 208:1862–1868, 1969.Google Scholar
  33. 33.
    Lieberman JA, Yunis J, Egea E, et al: HLA-B38, DR4, Dqw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 47:945–948, 1990.Google Scholar
  34. 34.
    Claas FHJ, Abbott PA, Witvliet MD, et al: Drug Safety (Supplement 1) 7:3–6, 1992.Google Scholar
  35. 35.
    Sandoz, Inc. Clozaril New Drug Application. East Hanover, N.J.: Sandoz Pharmaceutical Corp. 1987.Google Scholar
  36. 36.
    Lieberman JA, Johns C, Kane JM, et al: Clozapine-induced agranulocytosis: Non-cross reactivity with other psychotropic drugs. Journal of Clinical Psychiatry 49:271–277, 1988.Google Scholar
  37. 37.
    Gerson SL, Meltzer H: Mechanisms of clozapine-induced agranulocytosis. Drug Safety (Supplement 1) 7:17–25, 1992.Google Scholar
  38. 38.
    Safferman AZ, Lieberman JA, Alvir JMJ, et al: Rechallenge in clozapine-induced agranulocytosis. (letter). Lancet 339:1296–1297, 1992.Google Scholar
  39. 39.
    Barnas C, Zwierzina H, Hummer M, et al: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in the treatment of clozapine-induced agranulocytosis: A case report. Journal of Clinical Psychiatry 53:245–247, 1992.Google Scholar
  40. 40.
    Weide R, Koppler H, Pfluger K-H, et al: Successful treatment of clozapine induced agranulocytosis with Granulocyte-Colony Stimulating Factor (G-CSF). British Journal of Haematology 80:557–559, 1992.Google Scholar
  41. 41.
    Cates M, Lusk K, Wells BG, et al: Nonleukopenic neutropenia in a patient treated with clozapine. New England Journal of Medicine 326:840–841, 1992.Google Scholar
  42. 42.
    Claas FHJ: Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacology 99:S113–117, 1989.Google Scholar
  43. 43.
    Mason RP, Fischer V: Possible role of free radical formation in drug-induced agranulocytosis. Drug Safety (Supplement 1) 7:45–50, 1992.Google Scholar
  44. 44.
    Pisciotta AV, Konings SA, Ciesemier LL, et al: On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Safety (Supplement 1) 7:33–44, 1992.Google Scholar
  45. 45.
    Pisciotta AV, Konings SA, Cronkite CE, et al: Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. Journal of Laboratory and Clinical Medicine 119(3):254–266, 1992.Google Scholar
  46. 46.
    Lader M: Experience with clozapine in the United Kingdom. Presented at the NIMH New Clinical Drug Evaluation Unit Program 31st Annual Meeting, Key Biscayne, Florida, May 28–31, 1991.Google Scholar
  47. 47.
    Stricker BHC, Tielens JAE: Eosinophilia with clozapine. Lancet 338:1520–1521, 1991.Google Scholar
  48. 48.
    Sandoz, Inc. Clozaril (Clozapine): The atypical antipsychotic. East Hanover, N.J.: Sandoz Pharmaceutical Corp. 1990.Google Scholar
  49. 49.
    Panteleeva GP, Tsutsulkovskaya MY, Belyaev BS, et al: Clozapine in the treatment of schizophrenic patients: an international multicenter trial. Clinical Therapeutics 10:57–68, 1987.Google Scholar
  50. 50.
    Szymanski S, Jody D, Leipzig R, et al: Anticholinergic delirium caused by re-treatment with clozapine. American Journal of Psychiatry 148:1752, 1991.Google Scholar
  51. 51.
    Patil VJ: Development of transient obsessive-compulsive symptoms during treatment with clozapine (letter). American Journal of Psychiatry 149:272, 1992.Google Scholar
  52. 52.
    Eklund, K: Supersensitivity and clozapine withdrawal. (letter) Psychopharmacology 91:135, 1987.Google Scholar
  53. 53.
    Perenyi A, Kunz E, Bagdy G: Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244, 1985.Google Scholar
  54. 54.
    Ekblom B, Erikkson K, Lindstrom LH: Supersensitivity psychosis after sudden clozapine withdrawal. Psychopharmacology 83:293–294, 1984.Google Scholar
  55. 55.
    Borison RL, Diamond BI, Sinha D, et al: Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin 24:260–263, 1988.Google Scholar
  56. 56.
    Alphs LD, Lee HS: Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Journal of Clinical Psychiatry 52:346–348, 1991.Google Scholar
  57. 57.
    Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry 135:1409–1410, 1978.Google Scholar
  58. 58.
    Singh H, Hunt JI, Vitello B, et al: Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. Journal of Clinical Psychiatry 135:319–321, 1990.Google Scholar
  59. 59.
    Cohen BM, Keck PE, Satlin A, et al: Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry 29:1215–1219, 1991.Google Scholar
  60. 60.
    Safferman AZ, Lieberman JA, Pollack S, et al: Clozapine and akathisia Biological Psychiatry. In press, 1992.Google Scholar
  61. 61.
    Pope HG, Cole JO, Chopas PT, et al: Apparent neuroleptic malignant syndrome associated with clozapine and lithium. Journal of Nervous and Mental Disease 174:493–495, 1986.Google Scholar
  62. 62.
    Muller T, Becker T, Fritze J: Neuroleptic malignant syndrom after clozapine plus carbamazepine. Lancet II:1500, 1988.Google Scholar
  63. 63.
    Miller DM, Sharafuddin MJA, Kathol RG: A case of clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52:99–101, 1991.Google Scholar
  64. 64.
    DasGupta K, Young A: Clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52:105–107, 1991.Google Scholar
  65. 65.
    Anderson ES, Powers PS: Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry 52:102–104, 1991.Google Scholar
  66. 66.
    Kane JM, Woerner M, Safferman A, et al: Does clozapine cause tardive dyskinesia. In submission.Google Scholar
  67. 67.
    de Leon J, Moral L, Camunas C: Clozapine and jaw dyskinesia: A case report. Journal of Clinical Psychiatry 52:494–495, 1991.Google Scholar
  68. 68.
    Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 41:369–371, 1991.Google Scholar
  69. 69.
    Tiihonen J, Nausiainen U, Hakola P, et al: EEG abnormalities associated with clozapine treatment. (letter) American Journal of Psychiatry 148:1486, 1991.Google Scholar
  70. 70.
    Haller E, Binder RL: Clozapine and seizures. American Journal of Psychiatry 147:1471–1475, 1990.Google Scholar
  71. 71.
    Simpson GM, Cooper TA: Clozapine plasma levels and convulsions. American Journal of Psychiatry 135:99–100, 1978.Google Scholar
  72. 72.
    Miller DD: Effect of phenytoin on plasma clozapine concentrations in two patients. Journal of Clinical Psychiatry 52:23–25, 1991.Google Scholar
  73. 73.
    Chiles JA, Cohen S, McNaughten A: Dropping objects: Possible mild cataplexy associated with clozapine. Journal of Nervous and Mental Disorders 175:663–664, 1990.Google Scholar
  74. 74.
    Sassim N, Grohmann R: Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 21:306–307, 1988.Google Scholar
  75. 75.
    Friedman LJ, Tabb SE, Worthington JJ, et al: Clozapine-a novel antipsychotic agent. (Letter to Editor) New England Journal of Medicine 325:518–519, 1991.Google Scholar
  76. 76.
    Mandel JD, Zengo A, Katz R, et al: Effect of adrenergic agents on salivary composition. Journal of Dental Research 54 (Special Issue):B27–33, 1975.Google Scholar
  77. 77.
    Ukai Y, Taniguchi TI, Kimura K: Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and disopropylfluorophosphonate in rat submaxillary glands. Archives Internationales et de Pharmacodynamie Therapie 297:148–157, 1989.Google Scholar
  78. 78.
    Kaniucki MD, Stefano FJG, Pevec CJ: Clonidine inhibits salivary secretion by activation of postsynaptic alpha2-receptors. Naunyn Schmiedelbergs Archives of Pharmacology 326:313–316, 1984.Google Scholar
  79. 79.
    Grabowski J: Clonidine treatment of clozapine-induced hypersalivation (letter). Journal of Clinical Psychopharmacology 12:69–70, 1992.Google Scholar
  80. 80.
    Szymanski S, Lieberman JA, Picou D, et al: A case report of cimetidine-induced clozapine toxicity. Journal of Clinical Psychiatry 52:21–22, 1991.Google Scholar
  81. 81.
    Kane JM, Cooper TB, Sacher EJ, et al: Clozapine: Plasma levels and prolactin response. Psychopharmacology 73:184–187, 1981.Google Scholar
  82. 82.
    Meltzer HY, Goode DJ, Schyve PM, et al: Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry 136:1550–1555, 1979.Google Scholar
  83. 83.
    Gonzales A, Lieberman J, Loebel A, et al: Weight gain and neuroleptic drugs: A review of the literature. In submission.Google Scholar
  84. 84.
    Leadbetter RA, Vieweg V: Clozapine-induced weight gain. American Journal of Psychiatry 147:1693–1694, 1990.Google Scholar
  85. 85.
    Lamberti JS, Bellnier T, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry 149:689–690, 1992.Google Scholar
  86. 86.
    Zeigler J, Behar D: Clozapine-induced priapism (letter). American Journal of Psychiatry 149:272–273, 1992.Google Scholar
  87. 87.
    Seftel AD, Saenz de Tejada I, Szetela B, et al: Clozapine-associated priapism: a case report. Journal of Urology 147:146–148, 1992.Google Scholar

Copyright information

© Human Sciences Press, Inc 1992

Authors and Affiliations

  • Jeffrey A. Lieberman
    • 1
    • 2
  • Allan Z. Safferman
    • 1
    • 2
  1. 1.Hillside HospitalLong Island Jewish Medical CenterUSA
  2. 2.Albert Einstein College of MedicineUSA

Personalised recommendations